newsfilter
← Latest News
PR Newswire·

EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA

TOKYO and CAMBRIDGE, Mass., Dec. 22, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: